Advertisement
UK markets closed

  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     

  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     

  • AIM

    779.67
    +6.64 (+0.86%)
     

  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     

  • Bitcoin GBP

    53,594.11
    +1,397.54 (+2.68%)
     

  • CMC Crypto 200

    1,393.26
    +62.66 (+4.71%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • DOW

    40,589.34
    +654.27 (+1.64%)
     

  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     

  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     

  • DAX

    18,417.55
    +118.83 (+0.65%)
     

  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     
PROPERTY:

8 champion homes in Olympic host cities

A selection of properties in former Games cities as Paris 2024 starts

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

DBV Technologies S.A.
·2-min read
DBV Technologies S.A.
DBV Technologies S.A.

Montrouge, France, February 27, 2023

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update.

Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:

  • United States: 1-866-777-2509

  • International: 1-412-317-5413

ADVERTISEMENT

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment